Prolonging survival of transplanted pancreatic cells

Details Prolonging survival of transplanted pancreatic cells Prolonging survival of transplanted pancreatic cells

1999-03-01

2002-01-29

Borin, Michael (Department: 1631)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S011400, C514S012200, C514S015800, C514S017400

Reexamination Certificate

active

06342479

ABSTRACT:

BACKGROUND OF THE INVENTION
Pancreas transplantation was developed as a treatment for Type I diabetes in 1966. Robertson, R. P., New Engl. J. Med. 327(26):1861 (1992). As a result of improved immunosuppression treatments, advances in surgical techniques, and enhanced availability of donors, the number of pancreas transplantations has increased since the later 1970s. The graft survival rate, however, still remains quite low, e.g., a one year survival rate of 72 percent and a three year survival rate of 54 percent. Kendall, et al., Pancreas and Islet Transplantation, The Endocrinologist 5:28-35 (1995). The suvival rate for islet cell transplantation is even lower wherein no patient has remained insulin-free for longer than one year. Diabetes 1993 Vital Statistics, pages 46-47 (American Diabetes Association, 1993).
SUMMARY OF THE INVENTION
The present invention relates to a method of prolonging the survival of transplanted pancreatic cells in a patient (e.g., a mammal such as a human). The method includes the step of administering a therapeutically effective amount of somatostatin or a somatostatin agonist to the patient. What is meant by “survival” is either the viability or the biological function (e.g., the insulin response to hyperglycemia) of the transplanted pancreatic cells. The somatostatin or somatostatin agonist may be administered parenterally, e.g., administered intravenously, subcutaneously, or by implantation of a sustained release formulation. The transplanted pancreatic cells may be a whole or partially intact pancreas, pancreatic islets, or isolated pancreatic cells. The cells may be autograft cells, allograft cells, or xenograft cells. In one embodiment, the patient is an insulin-dependent (e.g., Type I or late Type II diabetic).
Definition of “somatostatin agonist” will be defined below. A therapeutically effective amount depends upon the condition being treated, the route of administration chosen, and the specific activity of the compound used and ultimately will be decided by the attending physician or veterinarian. In one embodiment, the somatostatin agonist is administered to the patient during the pancreatic cell transplantation and continued until the transplanted cells have become established and fully functional in the patient. In another embodiment, the somatostatin agonist is administered for the lifetime of the cells (e.g., potentially the lifetime of the patient).
The somatostatin agonist may be injected parenterally, e.g., intravenously, into the bloodstream of the subject being treated. However, it will be readily appreciated by those skilled in the art that the route, such as intravenous, subcutaneous, intramuscular, intraperitoneal, enterally, transdermally, transmucously, sustained released polymer compositions (e.g., a lactide polymer or copolymer microparticle or implant), profusion, nasal, oral, etc., will vary with the condition being treated and the activity and bioavailability of the somatostatin agonist being used.
While it is possible for the somatostatin agonist to be administered as the pure or substantially pure compound, it may also be presented as a pharmaceutical formulation or preparation. The formulations to be used in the present invention, for both humans and animals, comprise any of the somatostatin agonists to be described below, together with one or more pharmaceutically acceptable carriers thereof, and optionally other therapeutic ingredients.
The carrier must be “acceptable” in the sense of being compatible with the active ingredient(s) of the formulation (e.g., capable of stabilizing peptides) and not deleterious to the subject to be treated. Desirably, the formulation should not include oxidizing agents or other substances with which peptides are known to be incompatible. For example, somatostatin agonists in the cyclized form (e.g., internal cysteine disulfide bond) are oxidized; thus, the presence of reducing agents as excipients could lead to an opening of the cysteine disulfide bridge. On the other hand, highly oxidative conditions can lead to the formation of cysteine sulfoxide and to the oxidation of tryptophane. Consequently, it is important to carefully select the excipient. pH is another key factor, and it may be necessary to buffer the product under slightly acidic conditions (pH 5 to 6).
The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the active ingredient(s) into association with the carrier which constitutes one or more accessory ingredients.
In general, the formulations for tablets or powders are prepared by uniformly and intimately blending the active ingredient with finely divided solid carriers, and then, if necessary, as in the case of tablets, forming the product into the desired shape and size.
Formulations suitable for parenteral (e.g., intravenous) administration, on the other hand, conveniently comprise sterile aqueous solutions of the active ingredient(s). Preferably, the solutions are isotonic with the blood of the subject to be treated. Such formulations may be conveniently prepared by dissolving solid active ingredient(s) in water to produce an aqueous solution, and rendering the solution sterile. The formulation may be presented in unit or multi-dose containers, for example, sealed ampoules or vials.
Formulations suitable for sustained release parenteral administrations (e.g., biodegradable polymer formulations) are also well known in the art. See, e.g., U.S. Pat. Nos. 3,773,919 and 4,767,628 and PCT Publication No. WO 94/15587.
The somatostatin or somatostatin agonist may also be administered with an immunosuppressive agent or insulin. Examples of immunosuppressive agents include cyclosporin, FK-506 glucocorticoids, and antibodies to T-cells.


REFERENCES:
patent: 4612302 (1986-09-01), Szabo et al.
patent: 4904642 (1990-02-01), Coy et al.
patent: 5538739 (1996-07-01), Bodmer et al.
Database Medline. AN:L89160832. Szende et al. Proc. Natl. Acad. Sci USA, 86(5), 1643-1647, Mar. 1989.*
Database CaPlus, DN: 111:71271. Bilgen et al. Transplant. Proc., 1989, 21(1, Book 3), 2829-30.*
Steiner et al.; Somatostatin: Progress in Segmental Pancreas Transplantation. An Expert Mental Study of Canine Duct-Occluded Grafts; Transplant. Proc. (1984), 16(3) abstract.
Bjork et al., “Glucose Regulation of the Autoantigen GAD 65 in Human Pancreatic Islets”, J. of Clinical Endocrinology and Metabolism 76:1574-1576, 1992.
Buhler et al., “Indications for Human Islet Transplantation: Chronic Pancreatitis and Cystic Fibrosis”, Transplantation Proceedings 27:3148-3149, 1995.
Eizirik et al., “Prolonged Exposure of Human Pancreatic Islets to High Glucose Concentrations In Vitro Impairs the Beta-Cell Function”, J. Clin. Invest. 90:1263-1268, 1992.
Grunt et al., “A Randomized Trial of a Somatostatin Analog for Preserving Beta Cell Function in Children With Insulin Dependent Diabetes Mellitus”, Freund Publishing House Ltd. 7:331-334, 1994.
Kendall et al., “Pancreas and Islet Transplantation”, The Endocrinologist 5:28-35, 1995.
Patel et al., “Subtype Selectivity of Peptide analogs For all Five Cloned Human Somatostatin Receptors (hsst 1-5)”, Endocrinology 135:2814-2817, 1994.
Ponder et al., “Pancreatic Beta Cell Rest Induced by Use of Somatostatin Analog in Newly-Diagnosed Children and Adolescents With Type I Diabetes Mellitus”, Metabolism & Diabetes p. 197A, 1168.
Pozo et al., “Endocrine Profile of a Long-acting Somotastatin Derivative SMS 201-995. Study in Normal Volunteers Following Subcutaneous Administration”, Acta Endocrinologica 111:433-439, 1986.
Raynor et al., “Cloned Somatostatin Receptors: Identification of Subtype-Selective Peptides and Demonstration of High Affinity Binding of Linear Peptides”, Molecular Pharmacology 43:838-844, 1993.
Reisine et al., “Molecular Biology of Somatostatin Receptors”, Endocrine Reviews 16:427-442, 1995.
Robertson, R. Paul, “Pancreatic and Islet Transplantation for Diabetes—Cures or Curiosities?”, Seminars in Medicine of the Beth Israel Hospit

Affiliated with

Also associated with

Rating

Prolonging survival of transplanted pancreatic cells does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Prolonging survival of transplanted pancreatic cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prolonging survival of transplanted pancreatic cells will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2864934